Relmada Therapeutics Inc.

07/16/2026 | Press release | Distributed by Public on 07/16/2026 05:06

Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

Jul 16, 2026 7:05 AM EDT

CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, "Relmada" or the "Company"), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Thursday, August 6, 2026 at 4:30 PM ET to discuss financial results for the second quarter ended June 30, 2026, and recent business progress.

Conference Call and Webcast Information:

  • Date: Thursday, August 6, 2026 at 4:30 PM ET
  • Participant Dial-in (US): 1-800-717-1738
  • Participant Dial-in (International): 1-646-307-1865
  • Webcast Access: Click Here

A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.

About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.

For more information, visit www.relmada.com

Investor Contact:
Brian Ritchie
LifeSci Advisors
[email protected]

Media Inquiries:Corporate [email protected]


Source: Relmada Therapeutics

Released July 16, 2026

Relmada Therapeutics Inc. published this content on July 16, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on July 16, 2026 at 11:06 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]